English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Background  To investigate the efficacy, safety, and tolerability of weekly docetaxel treatment in advanced non‐small cell lung cancer ( NSCLC ) patients in  K orea.    Methods  This prospective observational study included  K orean advanced  NSCLC  patients with  E astern  C ooperative  O ncology  G roup performance status <2 who received weekly monotherapy of docetaxel at a dose determined by the physician. Efficacy measurements included tumor response rate, overall survival ( OS ), progression‐free survival, and one‐year survival rate. Safety was analyzed through recorded incidences of adverse events ( AEs ), serious adverse events ( SAEs ), deaths, and other related safety parameters, along with their toxicity grades.    Results:   Of 274 patients analyzed, one patient achieved a complete response and 42 partial responses; thus, the overall response rate was 15.7%. The  OS  rate at baseline and at one‐year follow‐up was 38.3% and 33.8%, respectively.  AEs  were reported in 229 (83.6%) patients. The most frequently reported hematologic  AE  of grade ≥3 was a decrease in neutrophils, with 6.6% of the patients developing neutropenia. In non‐hematologic  AEs  of grade ≥3, the most common were infection with unknown absolute neutrophil count and death not associated with  C ommon  T erminology  C riteria for  A dverse  E vents ( CTCAE ) (4.7% each). The most common  SAE  reported was death, not associated with  CTCAE  (7.3%).    Conclusions  In  K orean patients, the weekly regimen of docetaxel monotherapy was safe and efficacious against advanced  NSCLC .

thoracic cancer

Safety and efficacy of single‐agent docetaxel ( T axotere) administered weekly in non‐small cell lung carcinoma patients in  K orea: An observational study